Market Place
Sourcing Support
Antengene to Present Selinexor Data at ASH 2024
05 Nov 2024 //
PR NEWSWIRE
Antengene`s Xpovio® Approved For Third Indication In South Korea
17 Oct 2024 //
PR NEWSWIRE
Antengene Gets Thailand FDA Approval To Commercialize Xpovio
24 Sep 2024 //
PHARMABIZ
Antengene To Commercialise XPOVIO In Thailand For Myeloma
23 Sep 2024 //
BIOSPECTRUM ASIA
Antengene Announces 2024 Interim Results, R&D And Commercial Progress
23 Aug 2024 //
PR NEWSWIRE
Antengene Announces XPOVIO® (Selinexor) Approved in Malaysia
05 Aug 2024 //
PR NEWSWIRE
XPOVIO (Selinexor) Approved For DLBCL In China, Offering New Treatment Option
05 Jul 2024 //
PR NEWSWIRE
Antengene`s XPOVIO® Approved For Reimbursement In South Korea
26 Jun 2024 //
PR NEWSWIRE
Antengene To Present One Oral and Four Abstracts at ASCO 2024
23 May 2024 //
PR NEWSWIRE
Antengene Announces One Oral and Three Poster Presentations at ASCO 2024
25 Apr 2024 //
PR NEWSWIRE
Antengene Presents Four Preclinical Posters at AACR 2024
05 Apr 2024 //
PR NEWSWIRE
Antengene Announces Full Year 2023 Financial Results
22 Mar 2024 //
PR NEWSWIRE
Antengene Initiates Ph II Dose Study of ATG-022 in China and Australia
20 Mar 2024 //
PR NEWSWIRE
Antengene Publishes Preclinical Paper on PD-L1/4-1BB Bispecific Antibody ATG-101
19 Mar 2024 //
PR NEWSWIRE
Antengene to Present Four Preclinical Abstracts at AACR 2024
05 Mar 2024 //
PR NEWSWIRE
Antengene Announces Inclusion of XPOVIO in National Reimbursement Drug List
14 Dec 2023 //
PR NEWSWIRE
Antengene Announces Inclusion of XPOVIO in 2023 China`s Drug List
13 Dec 2023 //
PR NEWSWIRE
Antengene Announces the Study of Anti-CD24 Monoclonal Antibody ATG-031
10 Dec 2023 //
PR NEWSWIRE
Antengene Presents Encouraging Clinical Data from Four Pipeline Programs
16 Nov 2023 //
PR NEWSWIRE
Antengene to Host 2023 R&D Day and Discuss Key Data with KOLs
07 Nov 2023 //
PR NEWSWIRE
Antengene Presents Results from Investigational Programs at SITC Annual Meeting
31 Oct 2023 //
PR NEWSWIRE
Antengene To Present Results From Five Studies at 2023 SITC Annual Meeting
27 Sep 2023 //
PR NEWSWIRE
Antengene Announces Phase I Study of Anti-CD24 Monoclonal Antibody ATG-031
21 Sep 2023 //
PR NEWSWIRE
Antengene Announces Interim Financial Results for 2023
25 Aug 2023 //
PR NEWSWIRE
Antengene, Hansoh Pharma enter partnership to commercialize Xpovio
12 Aug 2023 //
PHARMABIZ
Antengene Announces First Patient Dosed in the Nivolumab Evaluating ATG-017
17 Jul 2023 //
PR NEWSWIRE
Antengene Announces XPOVIO plus Bortezomib and Dexamethasone Included for Reimbursement by the PBS
31 May 2023 //
PR NEWSWIRE
Antengene Announces Antibody-Drug ATG-022 Granted Orphan Drug Designations
23 May 2023 //
PR NEWSWIRE
Antengene Announces Clearance of U.S. IND for Monoclonal Antibody ATG-031
17 May 2023 //
PR NEWSWIRE
Antengene to Release Latest Results from the TORCH-2 Trial
26 Apr 2023 //
PR NEWSWIRE
Antengene Announces Results for Full Year 2022
28 Mar 2023 //
PR NEWSWIRE
Antengene Announces Five Upcoming Presentations at the Annual Meeting
20 Mar 2023 //
PR NEWSWIRE
Antengene Enters into a Global Clinical Collaboration MSD to Evaluate ATG-037
27 Dec 2022 //
PRNEWSWIRE
Antengene Announces HREC Approval in Australia for the Phase I Trial of ATG-022
09 Dec 2022 //
BIONJ
Antengene appoints Amily Zhang as Chief Medical Officer
07 Dec 2022 //
BIOSPECTRUMASIA
Antengene Appoints Amily Zhang as its Chief Medical Officer
07 Dec 2022 //
PRNEWSWIRE
Antengene Presents Promising Results from Four Preclinical at the 2022 SITC
10 Nov 2022 //
PRNEWSWIRE
Antengene Receives U.S. FDA Clearance of IND for Phase I Trial of ATG-017
31 Oct 2022 //
PRNEWSWIRE
Antengene to Host Research and Development Day on November 15th and 17th, 2022
27 Oct 2022 //
PRNEWSWIRE
Antengene Announces Presentations at Society for Immunotherapy of Cancer Meeting
07 Oct 2022 //
PRNEWSWIRE
Antengene Announces ATG-101 Granted Orphan Drug Designation by the U.S. FDA
19 Sep 2022 //
PRNEWSWIRE
China-based startup Antengene accelerates expansion in APAC region
14 Sep 2022 //
BIOSPECTRUMASIA
Antengene to Present at Upcoming Industry Conferences
09 Sep 2022 //
PRNEWSWIRE
Antengene Announces XPOVIO® Included for Reimbursement by the PBS in Australia
31 Aug 2022 //
PRNASIA
Antengene doses first subject in Phase I cancer trial
03 Aug 2022 //
CLINICALTRIALSARENA
Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101
02 Aug 2022 //
PRNEWSWIRE
Antengene Announces HREC Approval in Australia for PI Trial of ATG-018
06 Jun 2022 //
PRNEWSWIRE
Antengene to Present Clinical Results of ATG-008 (Onatasertib) at the 2022 ASCO
01 Jun 2022 //
ASIAONE
Antengene Begins Dosing in PI/II SWATCH Study of XPOVIO
22 May 2022 //
PRNEWSWIRE
Antengene Announces XPOVIO Treatment Regimens
18 May 2022 //
PRNEWSWIRE
Antengene Announces Commercial Availability of XPOVIO Across Mainland China
15 May 2022 //
PRNEWSWIRE
Antengene Announces XPOVIO® (selinexor) Data to be Presented at EHA
13 May 2022 //
PRNEWSWIRE
Antengene Announces Addition of Multiple XPOVIO Treatment Regimens
12 May 2022 //
PRNEWSWIRE
Antengene to Participate in Three Upcoming Investor Conferences in May/June
05 May 2022 //
PRNEWSWIRE
China`s Antengene looks to start phase I trial in Australia
27 Apr 2022 //
BIOSPECTRUMASIA
Antengene Announces Publication of Five Posters at the 2022 AACR
11 Apr 2022 //
PRNEWSWIRE
TGA Approves Antengene`s XPOVIO for r/r and TCR Multiple Myeloma
09 Mar 2022 //
PRNEWSWIRE
Antengene receives Australia approval to initiate phase I trial of ATG-037
08 Feb 2022 //
PHARMABIZ
Antengene to Present at the 40th Annual J.P. Morgan Healthcare Conference
05 Jan 2022 //
ASIAONE
Antengene doses first participant in tumour treatment trial in Australia
20 Dec 2021 //
CLINICALTRIALSARENA
